CFO
FATE icon

Callan Family Office’s Fate Therapeutics FATE Stock Holding History

Callan Family Office’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Buy
+10,911
New +$20.2K ﹤0.01% 1208
2025
Q2 		– Sell
-82,024
Closed -$64.8K – 935
2025
Q1 		$64.8K Buy
+82,024
New +$101K ﹤0.01% 538

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Callan Family Office's FATE Position: Q2 2026 in Review

Callan Family Office opened a new position in Fate Therapeutics (FATE) in Q2 2026: 10,911 shares worth $29.5K. The stake represents ﹤0.01% of the portfolio and ranks #1208 among its holdings. This is a return to the name: Callan Family Office previously reported a position in FATE as recently as Q1 2025.

Callan Family Office first reported a position in FATE in Q1 2025 and has held it in 2 quarters since. The position peaked at $64.8K in Q1 2025. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Callan Family Office held 10,911 shares of Fate Therapeutics worth $29.5K as of Q2 2026.
  • Fate Therapeutics was a new Callan Family Office position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1208 holding.
  • Callan Family Office first reported a position in Fate Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Callan Family Office's Fate Therapeutics position peaked at $64.8K in Q1 2025.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.